These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

2766 related articles for article (PubMed ID: 20068163)

  • 1. Drug combination studies and their synergy quantification using the Chou-Talalay method.
    Chou TC
    Cancer Res; 2010 Jan; 70(2):440-6. PubMed ID: 20068163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies.
    Chou TC
    Pharmacol Rev; 2006 Sep; 58(3):621-81. PubMed ID: 16968952
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug combination studies and their synergy quantification using the Chou-Talalay method--letter.
    Ashton JC
    Cancer Res; 2015 Jun; 75(11):2400. PubMed ID: 25977339
    [No Abstract]   [Full Text] [Related]  

  • 4. Synergistic combination of microtubule targeting anticancer fludelone with cytoprotective panaxytriol derived from panax ginseng against MX-1 cells in vitro: experimental design and data analysis using the combination index method.
    Zhang N; Fu JN; Chou TC
    Am J Cancer Res; 2016; 6(1):97-104. PubMed ID: 27073727
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The mass-action law based algorithms for quantitative econo-green bio-research.
    Chou TC
    Integr Biol (Camb); 2011 May; 3(5):548-59. PubMed ID: 21403972
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Preclinical versus clinical drug combination studies.
    Chou TC
    Leuk Lymphoma; 2008 Nov; 49(11):2059-80. PubMed ID: 19021049
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rational approach to the clinical protocol design for drug combinations: a review.
    Chang TT; Chou TC
    Acta Paediatr Taiwan; 2000; 41(6):294-302. PubMed ID: 11198934
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Computerized quantitation of synergism and antagonism of taxol, topotecan, and cisplatin against human teratocarcinoma cell growth: a rational approach to clinical protocol design.
    Chou TC; Motzer RJ; Tong Y; Bosl GJ
    J Natl Cancer Inst; 1994 Oct; 86(20):1517-24. PubMed ID: 7932806
    [TBL] [Abstract][Full Text] [Related]  

  • 9. An improved model for the analysis of combined antimicrobials: a replacement for the Chou-Talalay combination index method.
    Anastasiadi M; Polizzi K; Lambert RJW
    J Appl Microbiol; 2018 Jan; 124(1):97-107. PubMed ID: 29080234
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The mass-action law based algorithm for cost-effective approach for cancer drug discovery and development.
    Chou TC
    Am J Cancer Res; 2011; 1(7):925-54. PubMed ID: 22016837
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synergistic potential of dual andrographolide and melatonin targeting of metastatic colon cancer cells: Using the Chou-Talalay combination index method.
    Banerjee V; Sharda N; Huse J; Singh D; Sokolov D; Czinn SJ; Blanchard TG; Banerjee A
    Eur J Pharmacol; 2021 Apr; 897():173919. PubMed ID: 33577837
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Investigating antimalarial drug interactions of emetine dihydrochloride hydrate using CalcuSyn-based interactivity calculations.
    Matthews H; Deakin J; Rajab M; Idris-Usman M; Nirmalan NJ
    PLoS One; 2017; 12(3):e0173303. PubMed ID: 28257497
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Multiple drug effect analysis with confidence interval.
    Belen'kii MS; Schinazi RF
    Antiviral Res; 1994 Sep; 25(1):1-11. PubMed ID: 7811057
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic Interactions between Hepatitis B Virus RNase H Antagonists and Other Inhibitors.
    Lomonosova E; Zlotnick A; Tavis JE
    Antimicrob Agents Chemother; 2017 Mar; 61(3):. PubMed ID: 27956427
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessing the Effect of Mycotoxin Combinations: Which Mathematical Model Is (the Most) Appropriate?
    Kifer D; Jakšić D; Šegvić Klarić M
    Toxins (Basel); 2020 Feb; 12(3):. PubMed ID: 32121330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Synergistic apoptotic effect of the combination of diosgenin and TRAIL on non-small-cell lung cancer cell line A549 evaluated with the Chou-Talalay method].
    He Y; Wang JS; Zhang P; Zhang WJ; Huang QL; Hua ZC
    Yao Xue Xue Bao; 2013 Jan; 48(1):45-51. PubMed ID: 23600140
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Drug combinations and effect parameters of zidovudine, stavudine, and nevirapine in standardized drug-sensitive and resistant HIV type 1 strains.
    Zhu QY; Scarborough A; Polsky B; Chou TC
    AIDS Res Hum Retroviruses; 1996 Apr; 12(6):507-17. PubMed ID: 8679306
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Performance and sample size requirements of Bayesian methods for binary outcomes in fixed-dose combination drug studies.
    Holt MM; Stamey JD; Seaman JW; Young DM
    J Biopharm Stat; 2009; 19(1):120-32. PubMed ID: 19127471
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Schedule-dependent synergism between raltitrexed and irinotecan in human colon cancer cells in vitro.
    Aschele C; Baldo C; Sobrero AF; Debernardis D; Bornmann WG; Bertino JR
    Clin Cancer Res; 1998 May; 4(5):1323-30. PubMed ID: 9607593
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation.
    Bahri M; Fleurence J; Faraj S; Ben Mostefa Daho M; Fougeray S; Birklé S
    J Vis Exp; 2019 Jan; (143):. PubMed ID: 30735151
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 139.